IDXX
IDEXX Laboratories, Inc. Common Stock
$556.73
장중 · Vol 15.1K · 52주 $518.55–$769.98 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $543.97 · Aug 31, 2026
IDXX 가격 추세
종가
$543.97
시가
$547.68
고가
$548.18
저가
$543.62
30초 브리핑
IDXX 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 15%
연중 저점권입니다. 반등 신호보다 하락 원인을 먼저 확인하세요.
Forward P/E 33.3배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.1배
거래량은 최근 평균 범위입니다.
2026-11-02
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
IDXX 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
One IDEXX Drive · Westbrook, ME, United States · 직원 11,000명
시가총액
$43.86B
Trailing P/E
39.1
최근 12개월 이익 기준
Forward P/E
33.3
이익 증가 기대 반영
EPS (TTM)
$14.25
배당 수익률
—
배당성향
0.0%
베타
1.54
시장보다 민감
ROE
74.2%
P/B
27.23
EV/EBITDA
27.5
52주 범위
$518.55 – $769.98
현재 위치 15%
거래량
485.8K
20일 평균 431.3K · 1.1배
애널리스트 의견
매수 57%
총 14명 · 0m
DITM LEAPS Analysis
IDXX 장기 DITM 콜옵션을 진입 적합도 순으로 비교
해당 종목의 옵션 데이터가 없습니다.
재무제표
IDXX 연간 손익·현금흐름·재무상태
매출 성장률
+10.4%
최근 연간 YoY
EPS 성장률
+22.6%
최근 연간 YoY
영업이익률
31.6%
최근 연간
FCF 마진
24.2%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $4.30B+10.4% | $3.90B+6.5% | $3.66B+8.7% | $3.37B |
| 매출총이익 | $2.66B+11.8% | $2.38B+8.6% | $2.19B+9.3% | $2.00B |
| 영업이익 | $1.36B+20.5% | $1.13B+2.8% | $1.10B+22.1% | $898.76M |
| 순이익 | $1.06B+19.3% | $887.87M+5.1% | $845.04M+24.4% | $679.09M |
| 희석 EPS | $13.08+22.6% | $10.67+6.1% | $10.06+25.3% | $8.03 |
| EBITDA | $1.51B+18.7% | $1.27B+4.4% | $1.22B+20.4% | $1.01B |
| 영업현금흐름 | $1.18B+27.2% | $929.00M+2.5% | $906.51M+66.9% | $542.98M |
| 잉여현금흐름 | $1.04B+30.8% | $798.08M+3.3% | $772.88M+101.2% | $384.15M |
| 총자산 | $3.35B+1.7% | $3.29B+1.0% | $3.26B+18.7% | $2.75B |
| 총부채 | $976.06M-1.1% | $986.95M-7.5% | $1.07B-27.4% | $1.47B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
IDXX 실적·배당 일정
매출 하단
$1.18B
EPS 하단
$3.37
매출 상단
$1.20B
실적 발표일
2026-11-02
D-62
EPS 상단
$3.91
매출 컨센서스
$1.19B
EPS 컨센서스
$3.71
뉴스
IDXX 관련 최신 기사
제품·기술Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?
IDEXX Laboratories has struggled to keep pace with the broader market over the past year, but Wall Street still sees plenty of room for the stock to recover, with analysts maintaining a moderately bullish outlook on its prospects.
Barchart · Aug 26, 2026
실적Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
Zacks · Aug 21, 2026
제품·기술Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Focused Growth Fund”. A copy of the letter can be downloaded here. In the second quarter, the Baron Focused Growth Fund achieved a 13.26% gain, still trailing the Russell 2500 Growth Index’s 24.02% return. The underperformance was driven by ongoing concerns […]
Insider Monkey · Aug 20, 2026
- 실적
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.
Zacks · Aug 20, 2026
- 제품·기술
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
Zacks · Aug 19, 2026
제품·기술IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
IDEXX Laboratories (NASDAQ:IDXX) outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to incre
MarketBeat · Aug 14, 2026
실적Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?
IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We’ll now examine how the new Catalyst proBNP Test and...
Simply Wall St. · Aug 13, 2026
실적IDEXX (IDXX) Q2 2026 Earnings Call Transcript
Diagnostic innovations fuel 10% CAG recurring revenue growth despite wellness visit pressure.
Motley Fool · Aug 11, 2026
- 일반
Here is Why Growth Investors Should Buy Idexx (IDXX) Now
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Zacks · Aug 6, 2026
- 실적
Zoetis cuts annual forecasts as pet healthcare demand slows
Aug 6 (Reuters) - Animal health company Zoetis cut its annual forecasts on Thursday after missing Wall Street estimates for second-quarter revenue, as softer demand for pet healthcare products and
Reuters · Aug 6, 2026
홀더
IDXX 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
96.8%
기관 보유 (유동주식)
97.1%
내부자 보유
0.2%
기관 수
1,860
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 8.17M | $4.55B | 10.4% | -2.3% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 5.15M | $2.87B | 6.5% | -0.6% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 3.90M | $2.17B | 5.0% | -0.4% | Jun 30, 2026 |
| State Street Corporation | 3.75M | $2.09B | 4.8% | 2.0% | Jun 30, 2026 |
| Invesco Ltd. | 3.61M | $2.01B | 4.6% | 7.8% | Jun 30, 2026 |
| Geode Capital Management, LLC | 2.56M | $1.43B | 3.3% | -3.7% | Jun 30, 2026 |
| BAMCO Inc. | 1.98M | $1.10B | 2.5% | 21.0% | Jun 30, 2026 |
| Morgan Stanley | 1.36M | $754.93M | 1.7% | 3.0% | Jun 30, 2026 |
| Bank Of New York Mellon Corporation | 1.19M | $664.32M | 1.5% | -20.7% | Jun 30, 2026 |
| Arrowstreet Capital, Limited Partnership | 1.07M | $594.03M | 1.4% | 27.2% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.